ArticleInternational journal of pharmaceutics: X2026
Folate-mediated inflammatory microenvironment-responsive nanocarriers for the delivery of Moringa A to target NLRP3 for the treatment of viral pneumonia.
Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytokine storm triggered by respiratory viral infection is the core pathogenic mechanism of severe pneumonia, and excessive activation of the NLRP3 inflammasome is a critical link in inducing this storm and subsequent lung tissue damage. This study targets the NLRP3 inflammasome to investigate the therapeutic effects, mechanisms of action, and targeted delivery advantages of folic acid-modified nanoparticles encapsulating Moringa A (MA NPs) for viral pneumonia. Utilizing techniques such as cellular experiments, mouse model validation, molecular docking, bio-layer interferometry (BLI), immunohistochemistry, immunofluorescence, and histopathology, this study systematically analyzed the effects of MA NPs on the NLRP3 inflammasome pathway, pyroptosis, macrophage polarization, and lung tissue injury, while also validating the targeting efficacy of the folic acid-modified nanodelivery system. The results showed that MA NPs significantly reduced the expression of NLRP3, ASC, Caspase-1, and GSDMD in H1N1 virus-infected cells, decreased the levels of pyroptosis-related cytokines, and MA was confirmed to be an NLRP3 inhibitor. In mouse models, MA NPs reduced the lung index, downregulated the expression of pro-inflammatory cytokines in lung tissue, and alleviated pathological and ultrastructural damage to lung tissue. Furthermore, MA NPs inhibited the excessive activation of the NLRP3 inflammasome and promoted the polarization of macrophages from the M1 phenotype to the M2 phenotype, thereby alleviating the pulmonary inflammatory microenvironment. Therefore, MA NPs can repair lung tissue damage by inhibiting excessive activation of the NLRP3 inflammasome and regulating macrophage polarization, and combined with the folic acid-targeted delivery system, achieve precision treatment for viral pneumonia. This provides a new approach and experimental basis for the synergistic intervention of viral pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.